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Abstract: An intravenous (i.v.) formulation of mycophenolate mofetil
(MMF; CellCept®, Roche Pharmaceuticals, Inc., Palo Alto, CA) that
will enable its administration to patients unable to tolerate oral medica-
tion is available. Two separate studies, an open-labeled pharmacoki-
netic (PK) study and a double-blind safety study, were performed.
Within 24 h after transplant, 153 (safety study) and 45 (PK study) first
or second renal transplant recipients were started on i.v. MMF 1 g
Q12h or placebo (used in the safety study only, 2:1 MMF:placebo),
given over 2 h via a dedicated peripheral venous catheter. In the safety
study, per os (p.o.) MMF (1g Q12h) or placebo was administered,
starting within 72 h after transplant, whereas in the PK study, p.o.
MMF was started on the evening of day 5. Sequential blood samples
obtained on study days 5 (i.v. MMF) and 6 (p.o. MMF) before and up
to 12 h after the AM dose were analyzed for mycophenolic acid
(MPA) and MPA glucuronide (MPAG) concentrations by high-perfor-
mance liquid chromatography. The area under the concentration curve
(AUC) was calculated using the linear trapezoidal rule. The MPA
AUC0–12 was higher for i.v. MMF than p.o. MMF (40.8911.4 mg·h/
mL vs. 32.9915, pB0.001). There were no other significant PK differ-
ences for plasma MPA or MPAG. In the safety study (n=98 i.v.
MMF vs. n=55 placebo), 11 patients (11%, i.v. MMF) and 4 patients
(7%, placebo) discontinued their use of the drug because of an adverse
event (AE). Overall, AEs were similar between i.v. MMF and placebo.
Injection site phlebitis (4%) and thrombosis (4%) were observed only
with i.v. MMF. MMF i.v. 1 g twice daily (b.i.d.) should provide effi-
cacy at least equivalent to p.o. MMF without increased toxicity, and it
provides an acceptable alternative dose form in the immediate period
after transplant.
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Mycophenolate mofetil (MMF; CellCept, Roche
Pharmaceuticals, Inc., Palo Alto, CA), a prodrug
immunosuppressive agent, has been approved for
the prevention of rejection of heart and kidney
transplants (1–4). Following oral administration,
MMF undergoes rapid and extensive absorption
and complete presystemic hydrolysis to mycophe-
nolic acid (MPA), the active immunosuppressant
1 Present address: Roche Global Development, 3401 Hillview
Avenue, Palo Alto, CA 94304-1397
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species (5), by both liver and plasma esterases.
MPA is a potent and specific inhibitor of de no6o
purine synthesis. As a result of this inhibition, the
proliferation of both T and B lymphocytes is
blocked (6) and antibody production is inhibited
(7, 8). MPA, in turn, is almost completely metabo-
lized to form the phenolic glucuronide of MPA
(MPAG), which is not pharmacologically active
(6).
An intravenous (i.v.) formulation of MMF has
been recently released. The availability of such a
formulation enables MMF to be administered to
patients unable to tolerate oral medication. Fol-
lowing intravenous administration, MMF is also
rapidly hydrolyzed with a half life of only a few
minutes to MPA (5). In pharmacokinetic (PK)
studies, i.v. MMF has been administered to nor-
mal volunteers (9) and to a limited number of renal
and hepatic transplant recipients in the immediate
postoperative period. When given to normal indi-
viduals, Cmax was higher (47.290.3) after i.v. dos-
ing than oral dosing (34.097.1). The MPA area
under the concentration curve (AUC) from time 0
to 24 h was significantly higher following i.v. ad-
ministration compared to per os (p.o.) administra-
tion, but the total AUC was statistically
equivalent. Tmax was similar (9, 10). Unpublished
data from a small open-labeled study of the phar-
macokinetics of MMF (1.5 g twice daily [b.i.d.])
p.o., or i.v. infusions of 1 or 3 h in duration, or as
a continuous infusion to renal allograft recipients
showed that: the MPA AUC values were relatively
independent of the infusion time (1); the interdos-
ing-interval MPA AUC values were comparable
for the same i.v. and p.o. dose of MMF (2); and
that the MPA Cmax values were inversely related to
infusion time (3). From the Cmax data obtained, it
was estimated that an i.v. MMF dose of 1 g b.i.d.
administered over 2 h was likely to result in peak
plasma MPA concentrations comparable to those
following administration of the same dose of p.o.
MMF. These data formed the basis for the dosing
schedule employed in the present study.
The present study analyzes the results of two
related studies (MYCS2172 and MYCS2734) in de
no6o renal transplant patients in the immediate
postoperative period. Only a single dose level of
i.v. MMF (1 g b.i.d.), the dose of MMF currently
recommended for renal transplant recipients, was
studied. The PK study (MYCS2734) was designed
primarily to compare the bioavailability and phar-
macokinetics of MPA after multiple i.v. dosing
when switching to p.o. capsules. The design of the
safety study allowed an unbiased comparison of
the safety of the two methods of administration.
Patients and methods
Both studies were approved by the institutional
review boards at each center. Written informed
consent was obtained and the patients were
screened for eligibility within 48 h prior to trans-
plantation. Patients were eligible if they were: re-
cipients of a first or second renal transplant
(single-organ transplant only); at least 18 yr of age;
able to receive p.o. and i.v. medication. Patients
were excluded if: they were pregnant or nursing;
had severe diarrhea or other gastrointestinal (GI)
disorders; had active peptic ulcer disease; if the
patient or the donor had serologic evidence of
HTLV-1, HIV, or HbsAg; had a malignancy or
history of malignancy; had a systemic infection;
had a white blood cell count less than 2500/mm3, a
platelet count less than 100000/mm3, or
hemoglobin less than 6 g/dL at the time of entry;
required concomitant therapy with azathioprine,
tacrolimus, rapamycin, or any investigational drug.
Antacids were not permitted during the PK study.
Patients who fulfilled the inclusion/exclusion crite-
ria were enrolled into the respective studies prior to
transplantation.
The safety and tolerability study was a random-
ized, multicenter, double-blind study (for the first 5
d, with an open-labeled follow-up) parallel group
design. Before transplantation, eligible patients
were randomized in a 2:1 ratio to groups desig-
nated ‘MMF i.v.–p.o.’ (blinded i.v. MMF 1 g
b.i.d. and oral placebo capsules) or ‘MMF p.o.–
p.o.’ (blinded i.v. placebo b.i.d. and p.o. MMF
capsules, 1 g b.i.d.) through study day 5, followed
by open-labeled p.o. MMF in both groups. Patient
randomization was stratified by the center. Treat-
ment with the i.v. study drug began within 24 h
after transplantation. Treatment with the p.o.
study drug was begun as soon as the patient could
take the study capsules, but must have been started
within 72 h after transplantation. Patients com-
pleted the study on study day 21. Subsequent ther-
apy was determined by the patient’s physicians.
The PK study was also a multicenter one. It was
open-labeled with only one treatment group.
Treatment with i.v. MMF began within 24 h after
transplantation, followed by a switch to p.o. MMF
on the evening of day 5. Patients completed the
study on day 6.
The MMF used for i.v. administration was sup-
plied as a lyophilized powder in glass vials contain-
ing the equivalent of 500 mg of MMF (542 mg of
MMF hydrochloride), polysorbate 80, and anhy-
drous citric acid. A matching placebo for i.v.
MMF contained 250 mg mannitol, 120 mg dex-
trose, polysorbate 80, riboflavin, and anhydrous
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citric acid. The pharmacist at each study site re-
constituted and prepared each dose of i.v. study
drug. The i.v. solution was prepared and adminis-
tered within 12 h of reconstitution. The i.v. solu-
tion of MMF or placebo was administered, if
possible, via a dedicated peripheral venous catheter
cleared with D5W prior to infusion of the study
drug. A central line could be used if a peripheral
line could not be established or if local irritation
developed. The i.v. solutions were infused via a
pump at a rate of 84 mL/h for 2 consecutive hours.
Other drugs were not to be given simultaneously
with MMF through the infusion line or mixed in
the infusion bag. If possible, in order to permit a
more accurate assessment of the local tolerance of
MMF, other drugs were not to be administered at
any time through the peripheral i.v. line for MMF.
Peripheral infusion sites were changed every 72 h.
The MMF and placebo used for oral administra-
tion were supplied in blue, opaque, size c1 cap-
sules. MMF capsules contained 250 mg MMF,
pregelatinized starch, croscarmellose sodium, povi-
done (K-90), and magnesium stearate. Placebo
capsules contained pregelatinized starch, croscar-
mellose sodium, (K-90), and magnesium stearate.
The first day on which the patient received an
AM dose of i.v. study drug was designated as
study day 1. If the first dose of i.v. study drug was
administered PM, this day was designated as study
day 0. Subsequent doses of i.v. study drug were
given every 12 h through, and including, the morn-
ing or the evening of day 5 for the PK and safety
studies, respectively. For the safety study, the pa-
tients received a total of either 10 or 11 i.v. doses
of blinded study drug, depending on whether the
first dose was administered on study days 1 or 0,
respectively. For the PK study, the patients re-
ceived a total of either 9 or 10 i.v. doses of open-la-
beled i.v. MMF, depending on whether the first
dose was administered on study days 1 or 0,
respectively.
For the safety study, the first dose of oral study
drug was administered as soon as the patient could
take the capsules. Once oral dosing was initiated,
patients received their study capsules at the same
time as the start of their i.v. infusions for the
remainder of the double-blind phase of the study.
Four capsules of oral study drug were adminis-
tered b.i.d., to be swallowed intact. Open-label
MMF capsules were administered (1 g b.i.d.) on
study days 6 through 21. During the blinded phase
of the safety study (study days 0/1 through 5), no
modification of the dose of i.v. or p.o. study drug
was allowed. During the open-labeled oral dosing
phase (study days 6 through 21), if an adverse
event (AE) occurred the dose of MMF could be
reduced or interrupted as deemed appropriate by
the investigator.
For the PK study, p.o. MMF was administered
on the evening of day 5 and the morning of day 6.
No modification or interruption of the dose of i.v.
or p.o. study drug was allowed. If a patient missed
any doses of i.v. or p.o. MMF or was unable to
take four MMF capsules by the evening of study
day 5, the patient was excluded from the PK
evaluation.
The safety study was designed to make direct
comparisons between the two treatment groups
during the double-blind period. Since AEs oc-
curred between the time of the first i.v. dose (i.e.,
placebo) and the first dose of p.o. MMF for pa-
tients randomized to the p.o. MMF 2 g/d group,
patients were declared ‘on treatment’ at the time
they received their first i.v. placebo dose, so that
inspection of data for ‘delayed’ AEs was possible.
The summary of AEs – by treatment group –
collected while the patients were on double-blind
i.v. treatment included all AEs with onset date/
time on or after the date/time of the first i.v.
infusion up to the date/time of the first open-la-
beled oral dose. The summary of AEs during the
21 d of study included all AEs that occurred on the
day of the first dose of study drug up through the
first 21 d on study, and excluded all AEs that
occurred after the termination date for those pa-
tients prematurely terminating from the trial. The
summary of patients with AEs probably or possi-
bly related to the study drug used the relationship
as reported by the investigator, and also included
AEs for which the relationship was missing. All
opportunistic infections (OIs) were included in this
summary. Particular attention was paid to the pe-
ripheral i.v. infusion sites, that were inspected on
study days 0/1, 2, 3, 4, and 5. Beginning immedi-
ately prior to and continuing for 2 h after the end
of the initial infusion of study drug, patients were
monitored utilizing continuous electrocardiogram
(ECG), noninvasive arterial oxygen saturation
(SaO2), and supine blood pressure and pulse rates
obtained at 30-minute intervals. Pulse rates and
supine blood pressure were also recorded prior to,
30 min after the start, and at the completion of the
AM i.v. administration of study drug on study
days 3 and 5.
For the PK study, the primary objective was to
compare MMF bioavailability, determined by the
MPA AUC0–12, when switching from the 2-h i.v.
infusion on study day 5 to the 250-mg capsule
dosage form on study day 6. Patients fasted (water
permitted) overnight, beginning at 10 PM on the
nights prior to study days 5 and 6. Blood samples
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(5 mL each) for the measurement of MPA and
MPAG were obtained from either a peripheral or a
central line using a port dedicated to drawing
blood samples or by venipuncture. If MMF was
administered through a peripheral vein, blood
samples were not taken from the limb in which the
infusion was administered. If MMF was adminis-
tered through a central line, blood samples were
obtained from a peripheral vein. Blood samples
were collected in heparinized tubes immediately
before dosing (at 0 minutes), at 20, 30, 40, 60, 80,
100, 120, 140, and 160 min, and at 3, 4, 6, 8, and
12 h after the AM dose on study days 5 and 6.
Plasma samples were analyzed for MPA and
MPAG concentrations by high-performance liquid
chromatography (PHARMout Laboratories, Sun-
nyvale, CA). The limit of quantitation for MPA in
plasma was 0.1 mg/mL. The limit of quantitation
for MPAG in plasma was 4.0 mg/mL (2.38 mg/mL
in MPA-equivalent units). Actual times were used
in the calculation of all computed PK parameters.
AUC was calculated using the linear trapezoidal
rule. Cmax was determined by visual inspection of
the data, and Tmax was determined to be the time
at which it occurred. All MPAG concentrations
were expressed in MPA-equivalent units by multi-
plying all reported MPAG concentrations by the
ratio of MPA molecular weight to MPAG molecu-
lar weight (320.35/539.42). Concentrations below
the limit of quantitation of the assay were treated
as 0 in statistical summaries.
Statistics
For the safety study, the sample size was selected
empirically without formal assessment of study
power. All patients enrolled in the trial who re-
ceived at least one dose of study drug were in-
cluded in the assessment of safety. All safety data
were summarized using descriptive statistics. For
each patient, multiple or repeated AEs that
mapped to a common preferred term were con-
densed to a single AE.
No hypothesis testing was performed for efficacy
because of the short duration of the study and the
relatively small sample size. The number of full or
partial courses of immunosuppressives for the
treatment of rejection during the study was sum-
marized. A full course was at least 1 d of anti-thy-
mocyte globulin (ATG), or ALG, or anti-CD3
rnAb (OKT3), or corticosteroids administered for
at least 3 d with a total course dose of 600 mg or
more. A partial course was corticosteroids admin-
istered for 2 d or less, regardless of dose, or a total
dose of less than 600 mg at an average daily dose
of at least 100 mg.
For the PK study, the planned enrollment was
40 patients, with the expectation that at least 24
patients would be evaluable. Although this was not
a formal crossover bioequivalence study, the goal
of 24 evaluable patients was based on bioequiva-
lence criteria, assuming an intra-subject percentage
coefficient of variation of 22.5 for log-transformed
AUC0–12 ln(AUC0–12) (based on a previous unpub-
lished study), with 80% power to show bioequiva-
lence – assuming a difference of no more than 5%
between the two routes of administration. The
computed parameters were analyzed using
ANOVA with terms for patient and route of ad-
ministration. Statistical analyses were performed
using SAS, version 6.09. Ordinary confidence inter-
vals (CIs; 90% and 95%) for the difference in least
squares means were constructed and expressed as a
percentage (i.v. relative to p.o.) to compare the
bioavailability of the two routes of administration.
Results
Safety study
One-hundred and sixty patients (n=104 i.v.–p.o.,
and n=56 p.o.–p.o.) qualified to enter the safety
study. Twenty-eight patients were prematurely ter-
minated from the study. Seven patients, 6 in the
MMF i.v.–p.o. group and one in the MMF p.o.–
p.o. group, were randomized but never received
study drug and were not evaluated for safety. Of
these, 4 patients did not receive their transplant.
Two patients changed their mind about participat-
ing in the study. Fifteen patients prematurely ter-
minated from the trial because of AEs: 11 patients
(11%) in the i.v.–p.o. group and 4 patients (7%) in
the p.o.–p.o. group. These cases are discussed be-
low. One patient received 3 g/d of MMF to treat a
rejection episode. Three patients were terminated
because they received prohibited medications
(OKT3, tacrolimus, and tacrolimus, respectively).
One patient was terminated after 16 d because the
physician considered him to be over-immunosup-
pressed. One patient terminated for personal rea-
sons after having received the study drug for 15 d,
and one other for non-compliance.
Selected demographics of the 153 evaluable pa-
tients are summarized (Table 1). The two treat-
ment groups were well balanced for the number of
patients with a previous transplant, donor source,
panel reactive antibody, and cold ischemic time
(not shown). The number of HLA mismatches
between donor and recipient was slightly greater in
the MMF i.v.–p.o. group than in the MMF p.o.–
p.o. group. Induction therapy was administered to
42% of patients (41/98) in the MMF i.v.–p.o.




Table 1. Demographic summary: all evaluable patients enrolled in the safety
study
Treatment group
MMF i.v.–p.o. (n=98) MMF p.o.–p.o. (n=55)
Gender: n (%)
62 (63)Male 38 (69)








7 (7)Asian 7 (13)
13 (13) 6 (11)Black
66 (67)Caucasian 34 (62)
Hispanic 9 (9) 2 (4)
3 (3)Other 6 (11)
after the last dose for these prematurely terminated
patients, only 14 of 496 (2.8%) double-blind p.o.
doses were missed in 5 of 55 (9.1%) patients.
For the 153 patients who received study medica-
tion, Fig. 1 displays all specific AEs that occurred
in at least 20% of patients from the time of the first
dose of i.v. study medication until the time the
patient was placed on open-labeled p.o. MMF or
was terminated from the study (i.e., prematurely
terminated treatment during the i.v. phase of the
study). All but one patient (MMF i.v.–p.o. group)
experienced at least one AE during the double-
blind i.v. phase of the study. With the exception of
hypophosphatemia, these AEs, as well as those
reported for B20% of patients, were fairly evenly
distributed between the two treatment groups. A
small excess of cardiovascular events (chiefly ECG
abnormalities) were reported in the MMF i.v.–p.o.
group (not shown). These were without hemody-
namic consequences (e.g., arrhythmia, atrial fibril-
lation/flutter, and bigeminy).
In each group, 80% of patients (78/98 MMF
i.v.–p.o. patients; 45/55 MMF p.o.–p.o. patients)
received at least one dose of i.v. study medication
(i.e., MMF and placebo, respectively) via a periph-
eral infusion. Fifty of 78 patients (64%) in the
MMF i.v.–p.o. group and 29 of 45 patients (65%)
in the p.o.–p.o. group receiving one or more pe-
Ninety-nine percent of patients randomized to
the MMF i.v.–p.o. group received i.v. MMF for at
least 4 d. Ninety-one percent of the patients in the
MMF p.o.–p.o. group started oral dosing by 48 h.
Three patients in the MMF p.o.–p.o. treatment
group were terminated during the double-blind
study period for AEs. Excluding doses not taken




Fig. 2. Frequency of AEs that occurred at the peripheral infusion site for patients who received at least one dose of i.v. study
medication via a peripheral infusion.
ripheral infusion reported a peripheral infusion-site
reaction (Fig. 2). Venous thrombosis (4 patients,
4.1%), phlebitis, and hemorrhage were only re-
ported in the MMF i.v.–p.o. group. Only 1 patient
(MMF p.o.–p.o. group) was terminated from the
study for a peripheral infusion-site reaction (infu-
sion-site infiltration and edema).
Table 2 summarizes those events that occurred
in 20% or more of patients in at least one of the
treatment groups during the first 21 d of the study.
Hypophosphatemia occurred in 22/55 patients
(40%) during the i.v. placebo period, compared to
28/98 (28.6%) patients during i.v. MMF treatment;
however, the hypophosphatemia rate for the pe-
riod up to 21 d was similar for both groups (41.8%
and 39.8%, respectively). Peripheral edema oc-
curred in a similar number of patients during the
blinded i.v. treatment phase: 8/55 patients (14.5%)
receiving placebo compared to 12/98 (12.2%) pa-
tients receiving i.v. MMF; however, during the
study, peripheral edema was more frequent in the
i.v. MMF group 28/98 (28.6%) versus the p.o.
MMF group 8/55 (14.5%).
During the study, 33% of all evaluable patients
(51/153) experienced one or more severe AE as
graded by the investigator: 33% of patients (32/98)
in the MMF i.v.–p.o. group and 35% of patients
(19/55) in the MMF p.o.–p.o. group. Eighty-two
percent of all evaluable patients (126/153) experi-
enced one or more AEs that were judged by the
investigator to be probably or possibly related to
study medication: 83% of patients (81/98) in the
MMF i.v.–p.o. group and 82% of patients (45/55)
in the MMF p.o.–p.o. group. Forty percent of all
evaluable patients (61/153) experienced one or
more AE that led to dose reduction or interrup-
tion: 42% of patients (41/98) in the MMF i.v.–p.o.
group and 36% of patients (20/55) in the MMF
p.o.–p.o. group. Three patients experienced GI
hemorrhage that required hospitalization (1 in the
MMF p.o.–p.o. group and 2 in the MMF i.v.–p.o.
group). One additional patient (MMF i.v.–p.o.
group) was noted as having moderate gastric ero-
sions approximately 3 months after the study drug
was discontinued. One patient (MMF i.v.–p.o.
group) experienced a GI perforation. In general,
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Table 2. Comparison of number (%) of patients with AEs with onset during the first 21 d on studya to AEs with onset while on i.v. treatment
Preferred term for ad-Body system Number and percentage (%) of patients with adverse events
verse event
During first 21 d on During first 21 d on While on i.v. treatmentWhile on i.v. treatment
study (p.o., n=55)study (i.v., n=98) (p.o., n=55)(i.v., n=98)
Pain 41 (41.8) 26 (47.3)Body as 31 (31.6) 20 (36.4)
a whole Injection site reaction 23 (23.5) 15 (27.3) 23 (23.5) 15 (27.3)
Fever 23 (23.5) 10 (18.2) 20 (20.4) 7 (12.7)
Injection site pain 20 (20.4) 12 (21.8) 20 (20.4) 11 (20.0)
Reaction unevaluable 14 (14.3) 13 (23.6) 10 (10.2) 7 (12.7)
Abdominal pain 14 (14.3) 11 (20.0) 8 (8.2) 6 (10.9)
Metabolic and Hypophosphatemia 39 (39.8) 23 (41.8) 28 (28.6) 22 (40.0)
nutritional disease
Peripheral edema 28 (28.6) 8 (14.5) 12 (12.2) 8 (14.5)
Nausea 47 (48.0) 27 (49.1)Digestive 40 (40.8) 25 (45.5)
System Constipation 40 (40.8) 20 (36.4) 32 (32.7) 16 (29.1)
Diarrhea 32 (32.7) 12 (21.8) 19 (19.4) 6 (10.9)
Vomiting 33 (33.7) 11 (20.0) 26 (26.5) 10 (18.2)
Dyspepsia 19 (19.4) 11 (20.0) 16 (16.3) 9 (16.4)
Hypertension 44 (44.9) 22 (40.0) 30 (30.6) 19 (34.5)Cardiovascular system
Insomnia 16 (16.3) 13 (23.6) 11 (11.2)Nervous system 8 (14.5)
Hemic and lymph Anemia 22 (22.4) 9 (16.4) 19 (19.4) 8 (14.5)
system
a Occurring in 20% or more of patients in either treatment group during the first 21 d.
AEs were fairly evenly distributed between the two
treatment groups.
Ten percent of all evaluable patients (15/153)
prematurely terminated study treatment because of
AEs. These included 11% (11/98) of patients in the
MMF i.v.–p.o. group and 7% (4/55) patients in
the MMF p.o.–p.o. group. Only two patients in
the i.v.–p.o. group terminated during the double-
blind phase; one for atrial fibrillation and throm-
bosis, and the second for increased liver enzymes
(serum glutamic-oxaloacetic transaminase and
serum glutamic-pyruvic transaminase to 341 IU/L
and 425 IU/L, respectively). Likewise, only 3 pa-
tients in the p.o.–p.o. group terminated during the
double-blind phase; 2 for nausea and vomiting and
1 for injection site reaction.
Pulse rate and systolic and diastolic blood pres-
sure results showed no difference either within or
between groups when comparing baseline (pre-in-
fusion) measurements with those taken every 30
min for 4 h after the first dose of i.v. study drugs,
or between baseline measurements and those taken
after 30 minutes and at the end of the AM infu-
sions on study days 3 and 5 (not shown). Similarly
no differences were observed in results from con-
tinuous ECG and arterial oxygen saturation moni-
toring for 4 h after the first dose of i.v. study drugs
(not shown).
Seven percent of all evaluable patients (10/153)
developed an opportunistic OI (Table 3). Of the 6
patients in the MMF i.v.–p.o. group who devel-
oped an OI, 3 had received induction therapy (2
with OKT3 and one with ATG); one additional
patient in the MMF i.v.–p.o. group had received
augmented immunosuppression for the treatment
of a rejection episode prior to the onset of the OI.
Of the 4 patients in the MMF p.o.–p.o. group who
developed an OI, 1 had received induction therapy
(OKT3); none had received augmented immuno-
suppression for the treatment of a rejection
episode. The 1 patient who developed CMV
viremia/syndrome (MMF i.v.–p.o. group) was cy-
tomegalovirus (CMV) seropositive before trans-
Table 3. Summary of patients with opportunistic infections while on study




4 7Any opportunistic infection 6 6
34 64Candida, mucocutaneous
1 1Herpes simplex 21
0 0CMV viremia/syndrome 1 1
0 1Herpes zoster, cutaneous 20
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Table 4. Number of full course(s) of immunosuppressive therapy administered for rejection during the study
Treatment group
MMF i.v.–p.o. (n=98) MMF p.o.–p.o. (n=55)
n % n %
24 24.5 9 16.4Patients administered one or more full courses of immunosuppressive therapy
21 21.4One course 9 16.4
Two or more courses 3 3.1 0 0
Patients administered one or more full courses of immunosuppressives by type of immunosuppres-
sive
6 6.1 5OKT3/ATG/ALG only 9.1
Corticosteroids only 17 17.3 4 7.3
1OKT3/ATG/ALG plus corticosteroids 1.0 0 0
plant and received a kidney from a CMV seroposi-
tive donor.
Table 4 summarizes the use of full courses of
immunosuppressive therapy for the treatment of
rejection during the study. Additionally, 3 patients
in the MMF i.v.–p.o. group and 1 patient in the
MMF p.o.–p.o. group each received a single par-
tial course of corticosteroids for the treatment of
rejection during the study. Five patients (MMF
i.v.–p.o., n=4; MMF p.o.–p.o., n=1) experi-
enced graft loss during the study and underwent
transplant nephrectomy. For the i.v.–p.o. group,
the reason for the graft losses (and the days after
transplantation) were rejection (day 10), technical
complication (day 12), perinephric hematoma (day
12), and renal vein thrombosis (day 5). In the
MMF p.o.–p.o. group, one graft was lost at 8 d
from technical complications. No patient died dur-
ing the first 21 d of treatment.
PK study
A total of 45 patients from eight centers qualified
to enter the PK study. All patients enrolled into
this study received their transplants and at least
one dose of study drug. The demographics for the
patients in the PK study were similar to the dou-
ble-blind safety study (data not shown). Three
patients who completed the study normally were
not evaluable for pharmacokinetics because of
problems with blood sampling. Eleven patients did
not complete the PK study because of AE (n=5),
unsatisfactory therapeutic response (rejection, n=
1), prohibited medication (use of tacrolimus, n=
1), and other reasons (n=4, 3 for dialysis). The
safety profile was similar to that seen with the
double-blind study (data not shown).
Thirty-one patients were evaluable for the PK
analyses. Statistically significant differences in
mean plasma MPA concentration between the i.v.
and p.o. routes of administration were observed
for the 0.33-, 0.67-, 1.0-, 1.33-, 1.67-, 2.0-, and
2.33-h time points (Fig. 3). Statistically significant
differences between the routes were observed for
AUC0–12 (pB0.001) but not Cmax (p=0.252)
(Table 5). The apparent discrepancy between the
Cmax seen in Fig. 3 and the Cmax in Table 5 results
from the method of calculating the respective re-
sults. In Fig. 3, the data are the average of the
individual results at each defined time point. In
Table 5, the Cmax is the average of the individual
Cmax, regardless of the time at which it occurs. The
ordinary CIs (90%) for the difference in least
squares means were constructed and expressed as a
percentage (i.v. relative to p.o.) for the computed
parameters AUC0–12 Cmax and Tmax (Table 5). The
percentages for AUC0–12 and Cmax fall outside the
80–120% (non-transformed) or 80–125% (log-
transformed, not shown) bounds required to con-
clude that the formulations were bioequivalent.
The ratio for ln(AUC0–12) was 129% (90% CI of
119–139%) while that for ln(Cmax) was 120% (90%
CI of 101–143%).
Fig. 3. Mean pharmacokinetic (PK) profiles of mycophenolic
acid (MPA) over time (n=31). The i.v. MMF dose ()
compared to the p.o. MMF dose (	) produced significantly




Table 5. Plasma MPA and MPAG computed parameters, AUC0–12 and Cmax: i.v. versus p.o. dosing (n=31)
Ratio i.v./p.o. (%) 90% CIMMF i.v.a MMF p.o.a p-valueb
MPA
32.9915.0 B0.001 123.9 112.6, 135.2AUC0–12 (mg·h/mL) 40.8911.4
Cmax (mg/mL) 12.093.8 10.794.8 0.252 112.5 90.7, 134.3
Tmax (h) 1.5890.46 1.3391.05 0.231 118.8 87.4, 150.2
MPAG
AUC0–12 (mg·h/mL) 7209316 7469302 0.324 96.5 90.5, 102.4
Cmax (mg/mL) 74.6927.3 80.2927.5 0.086 93.0 86.4, 99.7
3.4292.03 0.713 70.9, 118.794.8Tmax (h) 3.6192.73
a Results are mean9SD obtained from the 31 evaluable patients.
b p-value compares results of MMF i.v. versus MMF p.o. for each PK parameter.
No statistically significant difference between the
i.v. and p.o. routes of administration was observed
for mean plasma MPAG concentrations at any
time point (Fig. 4), or for MPAG AUC0–12 and
Cmax (Table 5). As opposed to the findings with
MPA, the ordinary CIs (90 and 95%) for the
difference in least squares means for both AUC0–12
and Cmax fell within the 80–120% (non-trans-
formed) or 80–125% (log-transformed) bounds for
bioequivalence (not shown).
Discussion
Overall, the AE experience of patients receiving i.v.
MMF in the safety study (and confirmed in the
smaller open-labeled PK study) appeared to be
comparable to those receiving i.v. placebo during
both the 5-day, double-blind i.v. phase of the study
and the open-labeled oral follow-on phase. The
overall incidence of local site reactions of peripher-
ally administered infusions appeared to be unre-
lated to treatment with either i.v. MMF or
placebo. However, the peripheral i.v. infusion of
MMF appeared to be associated with a higher
incidence of local edema and inflammation. Injec-
tion site hemorrhage, phlebitis, and thrombosis
were observed only in the MMF i.v.–p.o. treat-
ment group, and may be caused by the i.v. MMF
formulation. Although none of these events re-
sulted in the interruption or discontinuation of i.v.
administration of MMF, a central venous line for
infusion may be a preferred alternative, if avail-
able. However, with the overall low incidence of
infusion-site complications, it is probably not
worth placing a central line solely for the adminis-
tration of i.v. MMF.
The difference in edema rates for the period up
to 21 d may be associated with overall differences
in the characteristics of the two groups that were
reflected in other measures of renal function. It is
improbable that this apparent post-i.v. treatment
increase was a consequence of a ‘delayed effect’ of
i.v. administration in the MMF i.v.–p.o. group.
The increased fever in the MMF i.v.–p.o. group
may reflect the more frequent use of ATGAM in
this group. Vomiting and diarrhea, known side
effects of p.o. MMF (1), were not avoided, and, in
fact, perhaps accentuated by the higher levels fol-
lowing the i.v. infusion of MMF. This suggests
that vomiting and diarrhea result from a systemic
effect of MPA and not simply a local GI effect.
Mean MPA ln(AUC0–12) during multiple-dose
i.v. treatment with MMF (1 g b.i.d. over 2 h) was
29% greater than that measured following the tran-
sition to p.o. MMF (1 g b.i.d. as 4×250 mg
capsules). The mean MPA ln(Cmax) associated with
the i.v. infusion was approximately 20% greater
than that following p.o. MMF. Similar results in a
normal volunteer study indicate that this effect is
not due to concurrent medications, postoperative
GI motility, or renal dysfunction (9). This indicates
that the 2-h infusion of i.v. MMF is not bioequiva-
lent to the 2 g p.o. dose of MMF. The MPA
concentration–time profile after i.v. administration
(Fig. 3), however, is nearly identical to that follow-
Fig. 4. Mean PK profiles of the phenolic glucuronide of MPA
(MPAG) over time (n=31). As opposed to the results with
MPA, MPAG levels following the i.v. MMF dose () were




ing p.o. dosing, indicating that a 2-h infusion
nearly mimics p.o. dosing. Based on the known
PK/PD relationship for MPA AUC, it is antici-
pated that a 1 g i.v. dose of MMF administered
twice daily according to the above regimen will
provide efficacy at least as good as p.o. treatment
(11). Shaw et al. (12), using p.o. MMF, reported
that renal transplant recipients with an average
MPA AUC of 40.9 mg·h/mL (similar to that seen
in this study with i.v. administration) had a rejec-
tion rate of 8.5%, which was considerably less than
the 25.5% rate seen with an AUC of 22.1 mg·h/mL.
With an AUC of 64.2 mg·h/mL the rejection rate
was decreased even further to 5.8%.
Despite the greater drug exposure, the safety
profile was comparable, at least over the short
term. It is uncertain if there will be an advantage
to using higher doses of i.v. MMF (e.g., 1.5 g
b.i.d.) in high risk groups or if this will lead to
increased toxicity. From a safety perspective, the
i.v. form of MMF (1 g administered over 2 h,
given twice daily) provides an acceptable alterna-
tive dose form to p.o. MMF in those patients
unable to take p.o. medication.
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